3 Stocks Raising The Drugs Industry Higher

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 104 points (-0.6%) at 17,824 as of Wednesday, May 6, 2015, 12:55 PM ET. The NYSE advances/declines ratio sits at 986 issues advancing vs. 2,035 declining with 119 unchanged.

The Drugs industry currently sits up 0.6% versus the S&P 500, which is down 0.3%. Top gainers within the industry include Herbalife ( HLF), up 20.3%, Usana Health ( USNA), up 19.8%, Incyte ( INCY), up 2.2%, Sanofi ( SNY), up 1.1% and GlaxoSmithKline ( GSK), up 0.8%. On the negative front, top decliners within the industry include Mylan ( MYL), down 2.7%, Teva Pharmaceutical Industries ( TEVA), down 1.6%, Pfizer ( PFE), down 1.2% and Gilead ( GILD), down 0.5%.

TheStreet would like to highlight 3 stocks pushing the industry higher today:

3. Vertex Pharmaceuticals ( VRTX) is one of the companies pushing the Drugs industry higher today. As of noon trading, Vertex Pharmaceuticals is up $1.87 (1.5%) to $124.02 on average volume. Thus far, 631,285 shares of Vertex Pharmaceuticals exchanged hands as compared to its average daily volume of 1.6 million shares. The stock has ranged in price between $122.09-$125.16 after having opened the day at $122.61 as compared to the previous trading day's close of $122.15.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Vertex Pharmaceuticals Incorporated engages in discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases in specialty markets. Vertex Pharmaceuticals has a market cap of $30.8 billion and is part of the health care sector. Shares are up 6.3% year-to-date as of the close of trading on Tuesday. Currently there are 8 analysts who rate Vertex Pharmaceuticals a buy, no analysts rate it a sell, and 10 rate it a hold.

TheStreet Ratings rates Vertex Pharmaceuticals as a sell. Among the areas we feel are negative, one of the most important has been an overall disappointing return on equity. Get the full Vertex Pharmaceuticals Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you liked this article you might like

Vertex Pharmaceuticals Could Be Headed Higher Once Again

Omeros Shares Lower After Completing Stock Offering, Juno Dips - Biotech Movers

10 High-Yielding Stocks to Own Ahead of a Surprising Late Summer Market Swoon

Vertex Pharmaceuticals: Looking East, West and to the Quants

Vertex Pharmaceuticals: Looking East, West and to the Quants